Roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer

炎症驱动的趋化因子在卵巢癌发病机制中的作用

基本信息

  • 批准号:
    7939737
  • 负责人:
  • 金额:
    $ 36.26万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-30 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Ovarian cancer is the fifth leading cause of cancer deaths among women because this deadly insidious disease is typically asymptomatic until the malignancy has reached beyond the ovaries. Although the precise etiology remains unknown, the increasing evidence indicates ovarian cancer is one of inflammation-associated cancers derived from inflammatory diseases. Compared with normal ovarian epithelial cells, ovarian cancer cells expressed highly tumor necrosis factor-1 (TNF) as a main proinflammatory cytokine that controls directly or indirectly chemokine networks. Growth-regulated oncogene (CXCL1) was significantly increased in ovarian cancer cells, and in the plasma and ascites of patients with ovarian cancer. Our recent studies have resulted that CXCL1, 2 and 8 are main inflammation-driven chemokines produced primarily and abundantly from ovarian cancer cells in response to inflammation. In other system, CXCL1 binds its specific receptor (CXCR2) and exert several functional roles such as cell proliferation, invasion, tumor formation and angiogenesis, which may be critical in the pathogenesis of ovarian cancer. These facts support that inflammation-driven chemokines promote ovarian cancer through inflammatory tumor microenvironments, which lead to massive ascites and widespread peritoneal dissemination as described in advanced ovarian cancer followed by the high mortality rate. In particular, genetic modifications such as p53 inactivity and EGFR/Akt overexpression are frequent in high- grade malignant ovarian cancer. The genetic modifications potentiate inflammation- driven chemokines, probably exacerbating the pathogenesis of ovarian cancer. However, the mechanisms inflammation-driven chemokines contribute to the pathogenesis of ovarian cancer are still poorly understood. The long-range goal of this research is to determine the specific contribution of chemokine networks to ovarian carcinogenesis. Targeting inflammation-driven chemokines will lead to a better understanding of the pathogenesis of ovarian cancer and provide important future applications for the potential use of chemokines as a biomarker and for use of specific chemokine receptor inhibitors and anti-inflammatory agents in the prevention and treatment of ovarian cancer. Preventing peritoneal dissemination and ameliorating ascites through blockage of inflammation-driven chemokines improve patient care and overall survival of women with ovarian cancer and other tumors related to inflammation. PUBLIC HEALTH RELEVANCE: Ovarian cancer is often diagnosed at an advanced stage after the cancer has spread beyond the ovary and results to the highest mortality of all cancers of the female reproductive system. Although the precise etiology remains unknown, the increasing evidence has emerged to indicate an impact of inflammation in the development, growth and progression of ovarian cancer. This project to define roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer will provide a firm foundation for future long-term survival reducing ovarian cancer risks and help to envisage much- needed novel therapies for ovarian cancer and other tumors related to inflammation.
描述(由申请人提供):卵巢癌是女性癌症死亡的第五大原因,因为这种致命的隐匿性疾病通常无症状,直到恶性肿瘤已经超出卵巢。虽然确切的病因尚不清楚,但越来越多的证据表明卵巢癌是由炎症性疾病发展而来的炎症相关性肿瘤之一。与正常卵巢上皮细胞相比,卵巢癌细胞高表达肿瘤坏死因子-1(TNF),TNF是一种主要的促炎细胞因子,直接或间接控制趋化因子网络。生长调节癌基因(CXCL 1)在卵巢癌细胞中,卵巢癌患者的血浆和腹水中显著增加。我们最近的研究表明,CXCL 1,2和8是主要的炎症驱动的趋化因子,主要由卵巢癌细胞在炎症反应中大量产生。在其他系统中,CXCL 1与其特异性受体CXCR 2结合,发挥多种功能作用,如细胞增殖、侵袭、肿瘤形成和血管生成,这可能在卵巢癌的发病机制中起关键作用。这些事实支持炎症驱动的趋化因子通过炎症性肿瘤微环境促进卵巢癌,这导致大量腹水和广泛的腹膜播散,如晚期卵巢癌中所述,随后是高死亡率。特别是,基因修饰如p53失活和EGFR/Akt过表达在高度恶性卵巢癌中很常见.基因修饰增强了炎症驱动的趋化因子,可能加剧了卵巢癌的发病机制。然而,炎症驱动的趋化因子导致卵巢癌发病的机制仍然知之甚少。这项研究的长期目标是确定趋化因子网络对卵巢癌发生的具体贡献。靶向炎症驱动的趋化因子将导致更好地了解卵巢癌的发病机制,并为趋化因子作为生物标志物的潜在用途以及在预防和治疗卵巢癌中使用特异性趋化因子受体抑制剂和抗炎剂提供重要的未来应用。通过阻断炎症驱动的趋化因子来预防腹膜播散和改善腹水,改善卵巢癌和其他炎症相关肿瘤患者的护理和总体生存率。 公共卫生关系:卵巢癌通常在癌症已经扩散到卵巢以外的晚期阶段被诊断出来,并且导致女性生殖系统所有癌症中死亡率最高。虽然确切的病因尚不清楚,但越来越多的证据表明炎症在卵巢癌的发展,生长和进展中的影响。该项目旨在确定炎症驱动的趋化因子在卵巢癌发病机制中的作用,将为未来长期生存提供坚实的基础,降低卵巢癌风险,并有助于设想卵巢癌和其他炎症相关肿瘤急需的新疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DEOK-SOO SON其他文献

DEOK-SOO SON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DEOK-SOO SON', 18)}}的其他基金

Roles of proinflammatory chemokines linking obesity and breast cancer
促炎趋化因子在肥胖和乳腺癌之间的作用
  • 批准号:
    8854751
  • 财政年份:
    2015
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of proinflammatory chemokines linking obesity and breast cancer
促炎趋化因子在肥胖和乳腺癌之间的作用
  • 批准号:
    9319657
  • 财政年份:
    2015
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of proinflammatory chemokines linking obesity and ovarian cancer
促炎趋化因子在肥胖和卵巢癌中的作用
  • 批准号:
    10012771
  • 财政年份:
    2011
  • 资助金额:
    $ 36.26万
  • 项目类别:
DISSECTING COX-1 RELATED GENE PATHWAYS IN OVARIAN CANCER
剖析卵巢癌中 COX-1 相关基因通路
  • 批准号:
    8166236
  • 财政年份:
    2010
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer
炎症驱动的趋化因子在卵巢癌发病机制中的作用
  • 批准号:
    7693473
  • 财政年份:
    2009
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer
炎症驱动的趋化因子在卵巢癌发病机制中的作用
  • 批准号:
    8515310
  • 财政年份:
    2009
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer
炎症驱动的趋化因子在卵巢癌发病机制中的作用
  • 批准号:
    8127815
  • 财政年份:
    2009
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of inflammation-driven chemokines in the pathogenesis of ovarian cancer
炎症驱动的趋化因子在卵巢癌发病机制中的作用
  • 批准号:
    8310032
  • 财政年份:
    2009
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of proinflammatory chemokines linking obesity and ovarian cancer
促炎趋化因子在肥胖和卵巢癌中的作用
  • 批准号:
    9765060
  • 财政年份:
  • 资助金额:
    $ 36.26万
  • 项目类别:
Roles of proinflammatory chemokines linking obesity and ovarian cancer
促炎趋化因子在肥胖和卵巢癌中的作用
  • 批准号:
    9356473
  • 财政年份:
  • 资助金额:
    $ 36.26万
  • 项目类别:

相似海外基金

Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
  • 批准号:
    10727507
  • 财政年份:
    2023
  • 资助金额:
    $ 36.26万
  • 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
  • 批准号:
    9194162
  • 财政年份:
    2016
  • 资助金额:
    $ 36.26万
  • 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
  • 批准号:
    496858-2016
  • 财政年份:
    2016
  • 资助金额:
    $ 36.26万
  • 项目类别:
    University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
  • 批准号:
    9201955
  • 财政年份:
    2015
  • 资助金额:
    $ 36.26万
  • 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
  • 批准号:
    8251289
  • 财政年份:
    2014
  • 资助金额:
    $ 36.26万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8302750
  • 财政年份:
    2012
  • 资助金额:
    $ 36.26万
  • 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
  • 批准号:
    267940
  • 财政年份:
    2012
  • 资助金额:
    $ 36.26万
  • 项目类别:
    Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8403458
  • 财政年份:
    2012
  • 资助金额:
    $ 36.26万
  • 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
  • 批准号:
    8472443
  • 财政年份:
    2012
  • 资助金额:
    $ 36.26万
  • 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
  • 批准号:
    8549297
  • 财政年份:
    2012
  • 资助金额:
    $ 36.26万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了